Today: 29 April 2026
Amphenol stock slides as Trump tariff threat shakes Wall Street; Jan. 28 earnings next up
21 January 2026
1 min read

Amphenol stock slides as Trump tariff threat shakes Wall Street; Jan. 28 earnings next up

NEW YORK, Jan 20, 2026, 21:08 EST — Market closed

  • Amphenol dipped roughly 1.3% Tuesday, but still held up better than several rivals amid a wider selloff.
  • The market fall came after new U.S. tariff threats targeted at Europe.
  • After sealing its recent deal, investors are shifting focus to Amphenol’s earnings call and guidance set for Jan. 28.

Amphenol Corporation shares closed Tuesday down 1.3% at $152.33, having fluctuated between $148.50 and $154.36 throughout the session. The stock was mostly flat in late trading.

Wall Street suffered its sharpest single-day drop in three months, dragged down by fresh concerns over U.S. trade policy. The S&P 500 tumbled 2.06%, while the Nasdaq dropped 2.39%, after President Donald Trump announced a new 10% tariff starting Feb. 1 on imports from several European nations, rising to 25% by June. “I’m not at the point yet … going to precipitate a correction,” said Jamie Cox, managing partner at Harris Financial Group. Reuters

Amphenol’s timing is critical, given the stock’s reputation as an “infrastructure” play—vulnerable to sell-offs when risk appetite fades. The Connecticut firm has highlighted AI-driven infrastructure investments and rising data communications demand as key growth engines. Reuters

Despite Tuesday’s drop, the connector and cable maker fared better than some peers. Amphenol saw about 10.6 million shares traded, well above its 50-day average of 7.9 million. The stock still sits roughly 2.5% shy of its Jan. 15, 52-week high. TE Connectivity, by comparison, tumbled 3.2% that day.

Amphenol announced on Jan. 12 that it has closed its acquisition of CommScope’s Connectivity and Cable Solutions unit. CEO R. Adam Norwitt described the deal as a lift to the company’s “fiber optic interconnect capabilities” in IT datacom and communications networks. The acquired business is projected to deliver roughly $4.1 billion in sales by 2026 and should add about $0.15 to diluted earnings per share that year, excluding acquisition-related costs. Amphenol Investor Relations

Investors are left sorting through what counts as “real demand” versus a simple unwind after a strong rally. They’ll also watch closely for signs that integration expenses are exceeding expectations or if orders linked to data-center expansions are slowing down.

Amphenol is set to report its fourth-quarter 2025 earnings with a conference call on Jan. 28 at 1:00 p.m. ET.

Yet there’s a “what could go wrong” vibe lingering. A deeper trade war could disrupt electronics supply chains and curb capital spending, pushing up volatility right when pricey industrial-tech stocks stumble.

Traders eyeing Wednesday’s session will focus on tariff headlines and interest rate developments. Amphenol is scheduled to release its next update on Jan. 28, providing fresh results and 2026 guidance.

Stock Market Today

  • Nasdaq Futures Rise Ahead of Fed Decision and Major Tech Earnings
    April 29, 2026, 9:10 AM EDT. Nasdaq futures gained 0.4% ahead of the Federal Reserve's policy decision and earnings reports from tech giants Alphabet, Microsoft, Amazon, and Meta. Markets are cautious following a broad sell-off in major indices driven by chip stock weakness linked to slowing growth at AI firm OpenAI. Investors await the Fed's stance on inflation and interest rates, with crude oil prices rising amid unresolved US-Iran tensions. The Fed is expected to hold rates steady in Jerome Powell's final meeting before his replacement, Kevin Warsh, awaits Senate approval. Key focus remains on AI capital expenditure and the potential for further rate hikes in 2024. Earnings from AbbVie, AstraZeneca, Total Energies, UBS, and GSK are also in focus.

Latest article

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Humana Stock Drops After Earnings Beat: Medicare Advantage Headwind Keeps Pressure On

Humana Stock Drops After Earnings Beat: Medicare Advantage Headwind Keeps Pressure On

29 April 2026
Humana beat first-quarter profit estimates, earning $10.31 per share adjusted, but shares fell over 6% premarket after it kept its 2026 profit outlook unchanged and cut its GAAP earnings forecast. Revenue rose to $39.65 billion. The insurer cited lower Medicare Star Ratings for the earnings decline and said medical and pharmacy costs are “slightly better” than expected. Competitors Centene, UnitedHealth, and Elevance recently raised their annual forecasts.
Silver price breaks $95 and then slips as Greenland tariff threat fuels haven rush
Previous Story

Silver price breaks $95 and then slips as Greenland tariff threat fuels haven rush

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Next Story

Stock Market Today 21.01.2026

Go toTop